The Chase Group was once again retained by Akcea Therapeutics to complete an extensive executive search on an accelerated timeline for a Senior Vice President, Global Medical Affairs, and the search was successfully completed in less than 60 days with the appointment of Dr. Christophe Hotermans. A seasoned medical affairs executive and industry veteran, Dr. Hotermans will lead the execution and development of worldwide medical strategies, activities, and operations as a member of the Akcea executive management team. Dr. Hotermans has 20+ years of experience, including more than 12 years in the biotechnology industry with roles in drug safety and medical affairs, both US and global. During this time, he launched five products across multiple therapeutic areas in specialty care and rare disease. His expertise in developing global medical strategies in these areas will be a great asset to Akcea as they continue to globally execute two commercial launches. The Chase Group appreciates a relational collaboration with the Akcea executive team and looks forward to the continued partnership as Akcea Therapeutics develops and commercializes products for patients living with serious and rare diseases.
To learn how The Chase Group can identify high caliber talent for your team, please contact karen@chasegroup.com.
Search Executed by The Chase Group, Inc. Results in Successful Appointment of Dr. Christophe Hotermans as SVP, Global Medical Affairs for Akcea Therapeutics
The Chase Group was once again retained by Akcea Therapeutics to complete an extensive executive search on an accelerated timeline for a Senior Vice President, Global Medical Affairs, and the search was successfully completed in less than 60 days with the appointment of Dr. Christophe Hotermans. A seasoned medical affairs executive and industry veteran, Dr. Hotermans will lead the execution and development of worldwide medical strategies, activities, and operations as a member of the Akcea executive management team. Dr. Hotermans has 20+ years of experience, including more than 12 years in the biotechnology industry with roles in drug safety and medical affairs, both US and global. During this time, he launched five products across multiple therapeutic areas in specialty care and rare disease. His expertise in developing global medical strategies in these areas will be a great asset to Akcea as they continue to globally execute two commercial launches. The Chase Group appreciates a relational collaboration with the Akcea executive team and looks forward to the continued partnership as Akcea Therapeutics develops and commercializes products for patients living with serious and rare diseases.
To learn how The Chase Group can identify high caliber talent for your team, please contact karen@chasegroup.com.
The Chase Group Successfully Completes Search for Vice President, Research & Development at Alexza Pharmaceuticals
Alexza Pharmaceuticals stands at the crossroads of innovation and advanced technology with a platform that has the potential to address unmet medical needs in neuroscience….
The Chase Group Successfully Places David Geller, MD as Head of Pulmonary & Rare Disease Clinical Development for Arcturus Therapeutics
The Chase Group (TCG) is pleased to announce the successful recruitment of David Geller, MD as the Vice President, Pulmonary and Rare Diseases Clinical Development…
Drug Safety Leadership Team Grows at Ionis Pharmaceuticals Through Continued Partnership with The Chase Group
Ionis Pharmaceuticals retained The Chase Group to identify and secure the next member of their drug safety leadership team to support a robust and continually…
The Chase Group Continues Successful Collaboration with Genmab Through Placement of Vice President, CDTL
The Chase Group, known for its thorough search capabilities and expertise in Life Sciences Executive Search, was retained by Genmab Pharmaceuticals to execute a critical…
The Chase Group Successfully Secures Vice President, Head of Medical Development for Checkmate Pharmaceuticals
Building on a 14+ year relationship with Chase, the Chief Medical Officer of Checkmate Pharmaceuticals retained The Chase Group to identify a critical hire for…
Search Executed by The Chase Group, Inc. Results in Successful Appointment of Dr. Christophe Hotermans as SVP, Global Medical Affairs for Akcea Therapeutics
The Chase Group was once again retained by Akcea Therapeutics to complete an extensive executive search on an accelerated timeline for a Senior Vice President,…